Bio-Rad last week reported a 3 percent uptick in fourth-quarter 2011 revenues in its overall business and Life Science segment, the latter driven primarily by strong sales in its core markets of electrophoresis, imaging, and real-time PCR-based gene expression.

In addition, Bio-Rad executives said that the digital PCR platform the company acquired in October along with biotech firm QuantaLife is expected to generate $20 million in sales in 2012; and that an increased investment in the platform would likely also drive up R&D costs at the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.